Edition:
Deutschland

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

104.35EUR
6 Dec 2019
Change (% chg)

€0.35 (+0.34%)
Prev Close
€104.00
Open
€104.05
Day's High
€104.85
Day's Low
€103.45
Volume
341,983
Avg. Vol
465,456
52-wk High
€110.35
52-wk Low
€85.84

About

Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Performance Materials. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and... (more)

Buy/Sell

Sell Hold Buy
2.52 Mean rating from 25 analysts

Overall

Beta: 1.01
Market Cap(Mil.): €12,352.97
Shares Outstanding(Mil.): 129.24
Dividend: 1.20
Yield (%): 1.26

German stocks - Factors to watch on November 20

BERLIN/FRANKFURT, Nov 20 The following are some of the factors that may move German stocks on Wednesday:

Photo

Merck KGaA raises 2019 guidance after Versum takeover

BERLIN German science and technology company Merck KGaA raised its full-year forecast for sales and adjusted earnings on Thursday after completing the takeover of semiconductor materials maker Versum Materials in October.

Photo

Merck KGaA raises 2019 guidance after Versum takeover

BERLIN German science and technology company Merck KGaA raised its full-year forecast for sales and adjusted earnings on Thursday after completing the takeover of semiconductor materials maker Versum Materials in October.

UPDATE 2-Merck KGaA raises 2019 guidance after Versum takeover

* Pharmaceuticals/lab supplies units plus FX effects boost result

Merck KGaA raises 2019 sales, earnings guidance in wake of Versum takeover

BERLIN, Nov 14 Germany's Merck KGaA on Thursday raised its full-year 2019 forecast for sales and adjusted earnings after completing the takeover of electronic materials maker Versum Materials in October.

German stocks - Factors to watch on November 14

BERLIN/FRANKFURT, Nov 14 The following are some of the factors that may move German stocks on Thursday:

ObsEva IVF nolasiban drug flops in key European trial

ZURICH, Nov 7 Swiss-listed drugmaker ObsEva said on Thursday it is abandoning the current programme for its drug prospect nolasiban after the agent aimed at boosting pregnancy following in-vitro fertilisation (IVF) failed a late-stage study in Europe.

German stocks - Factors to watch on October 29

BERLIN/FRANKFURT, Oct 29 The following are some of the factors that may move German stocks on Tuesday:

Deals of the day-Mergers and acquisitions

Oct 7 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.68%
Rohstoffe +0.93%
Industrie +0.59%
Konjunktur abhängige Waren & Dienstleistungen +0.56%
Konjunktur unabhängige Waren & Dienstleistungen +0.87%
Finanzindustrie +0.54%
Pharma +0.97%
Technologie +0.28%
Telekommunikation -0.03%

Nachrichten aus der Wirtschaft

Photo

Schweizer Börse legt zu - Swiss Re nach Spartenverkauf gesucht

Zürich Gute US-Konjunkturdaten haben der Schweizer Börse zum Wochenschluss Schub verliehen. Der SMI gewann rund ein Prozent auf 10.463 Punkte. Der stärkste Stellenaufbau in den USA seit zehn Monaten zeigte Händler zufolge, dass der US-Arbeitsmarkt in besserer Verfassung ist erwartet. Trotz des Schlussspurts verbuchte der Leitindex im Verlauf der gesamten Woche ein Minus von rund 0,3 Prozent.